<?xml version="1.0" encoding="UTF-8"?>
<p>These findings inform development of testing programs and policies at the country and regional levels, thereby attending to the first and fourth of the WHO’s GHSS strategic directions.
 <xref rid="hep41310-bib-0022" ref-type="ref">22</xref>, 
 <xref rid="hep41310-bib-0023" ref-type="ref">23</xref> These call, respectively, for characterizing populations at increased risk of exposure and for ensuring efficiency, cost‐effectiveness, and sustainability of programs.
 <xref rid="hep41310-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="hep41310-bib-0022" ref-type="ref">22</xref>, 
 <xref rid="hep41310-bib-0023" ref-type="ref">23</xref> With the constrained funding for HCV programming,
 <xref rid="hep41310-bib-0067" ref-type="ref">67</xref>, 
 <xref rid="hep41310-bib-0068" ref-type="ref">68</xref>, 
 <xref rid="hep41310-bib-0069" ref-type="ref">69</xref> the financial implications of poorly informed testing strategies and inefficient testing campaigns may cripple the political will to scale up test‐and‐treat programs, thus thwarting progress toward achieving the GHSS service coverage targets.
 <xref rid="hep41310-bib-0022" ref-type="ref">22</xref>, 
 <xref rid="hep41310-bib-0023" ref-type="ref">23</xref>, 
 <xref rid="hep41310-bib-0070" ref-type="ref">70</xref> The presented results indicate a real opportunity for MENA countries to establish and/or optimize efficient test‐and‐treat programs. Such programs would not only tackle existing infection and disease burden but also lead to a gradual decline in incidence, thus meeting GHSS targets and simultaneously achieving the 2030 elimination goal.
 <xref rid="hep41310-bib-0022" ref-type="ref">22</xref>, 
 <xref rid="hep41310-bib-0023" ref-type="ref">23</xref>, 
 <xref rid="hep41310-bib-0070" ref-type="ref">70</xref>
</p>
